The present disclosure provides crystalline polymorphic and amorphous forms of (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 1) or (S)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 2). The present disclosure further provides compositions comprising crystalline polymorphic and amorphous forms of Compound 1 or Compound 2 and an excipient, methods of making crystalline polymorphic or amorphous forms of Compound 1 or Compound 2, and methods of using crystalline polymorphic or amorphous forms of Compound 1 or Compound 2 to regulate gene expression in a cell or in a subject.
本公开提供(R)-
3,5-二甲基苯甲酸N-(1-叔丁基丁基)-N'-(2-乙基-3-
甲氧基苯甲酰)-
肼(化合物1)或(S)-
3,5-二甲基苯甲酸N-(1-叔丁基丁基)-N'-(2-乙基-3-
甲氧基苯甲酰)-
肼(化合物2)的结晶多态和非晶态形式。本公开还提供包含化合物1或化合物2的结晶多态和非晶态形式及赋形剂的组合物,制备化合物1或化合物2的结晶多态或非晶态形式的方法,以及使用化合物1或化合物2的结晶多态或非晶态形式在细胞或主体中调节
基因表达的方法。